Exelixis, Inc.

NasdaqGS:EXEL Stock Report

Market Cap: US$9.6b

Exelixis Valuation

Is EXEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EXEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$174.86
Fair Value
80.7% undervalued intrinsic discount
22
Number of Analysts

Below Fair Value: EXEL ($33.67) is trading below our estimate of fair value ($174.86)

Significantly Below Fair Value: EXEL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXEL?

Key metric: As EXEL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EXEL. This is calculated by dividing EXEL's market cap by their current earnings.
What is EXEL's PE Ratio?
PE Ratio20.6x
EarningsUS$466.92m
Market CapUS$9.58b

Price to Earnings Ratio vs Peers

How does EXEL's PE Ratio compare to its peers?

The above table shows the PE ratio for EXEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.7x
BMRN BioMarin Pharmaceutical
38x24.1%US$12.2b
SRPT Sarepta Therapeutics
87.9x29.9%US$11.4b
HALO Halozyme Therapeutics
18.8x17.3%US$7.3b
UTHR United Therapeutics
14.2x10.1%US$15.8b
EXEL Exelixis
20.6x20.1%US$9.6b

Price-To-Earnings vs Peers: EXEL is good value based on its Price-To-Earnings Ratio (20.6x) compared to the peer average (39.7x).

Price to Earnings Ratio vs Industry

How does EXEL's PE Ratio compare vs other companies in the US Biotechs Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.7x-56.1%US$7.99b
AGIO Agios Pharmaceuticals
2.9x-29.7%US$1.96b
INBX Inhibrx Biosciences
0.1x-135.7%US$196.29m
CTMX CytomX Therapeutics
4.9x-13.8%US$73.38m
EXEL 20.6xIndustry Avg. 17.5xNo. of Companies10PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EXEL is expensive based on its Price-To-Earnings Ratio (20.6x) compared to the US Biotechs industry average (17.5x).

Price to Earnings Ratio vs Fair Ratio

What is EXEL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXEL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.6x
Fair PE Ratio28.3x

Price-To-Earnings vs Fair Ratio: EXEL is good value based on its Price-To-Earnings Ratio (20.6x) compared to the estimated Fair Price-To-Earnings Ratio (28.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EXEL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$33.67
US$35.93
+6.7%
15.0%US$43.00US$23.00n/a22
Jan ’26US$33.30
US$33.56
+0.8%
13.9%US$40.00US$23.00n/a22
Dec ’25US$36.46
US$32.11
-11.9%
13.7%US$38.00US$23.00n/a22
Nov ’25US$34.12
US$32.11
-5.9%
13.7%US$38.00US$23.00n/a22
Oct ’25US$26.30
US$27.60
+5.0%
14.2%US$34.36US$18.00n/a22
Sep ’25US$26.03
US$27.38
+5.2%
14.6%US$35.07US$18.00n/a21
Aug ’25US$24.22
US$26.59
+9.8%
15.7%US$35.07US$17.00n/a22
Jul ’25US$22.25
US$26.59
+19.5%
15.7%US$35.07US$17.00n/a22
Jun ’25US$21.69
US$26.59
+22.6%
15.7%US$35.07US$17.00n/a22
May ’25US$21.93
US$26.76
+22.0%
15.3%US$35.07US$17.00n/a22
Apr ’25US$23.68
US$26.63
+12.5%
14.6%US$32.35US$18.00n/a21
Mar ’25US$22.24
US$26.63
+19.7%
14.6%US$32.35US$18.00n/a21
Feb ’25US$21.75
US$26.52
+21.9%
14.2%US$32.00US$18.00US$33.1521
Jan ’25US$23.99
US$26.44
+10.2%
15.2%US$32.00US$18.00US$33.3021
Dec ’24US$21.94
US$25.75
+17.4%
16.2%US$32.00US$18.00US$36.4619
Nov ’24US$21.02
US$25.68
+22.2%
16.3%US$32.00US$18.00US$34.1219
Oct ’24US$21.85
US$25.58
+17.1%
16.3%US$32.00US$18.00US$26.3019
Sep ’24US$22.74
US$25.00
+9.9%
17.2%US$32.00US$18.00US$26.0318
Aug ’24US$19.63
US$24.90
+26.9%
16.9%US$32.00US$17.00US$24.2217
Jul ’24US$19.11
US$25.31
+32.5%
16.6%US$32.00US$17.00US$22.2517
Jun ’24US$19.39
US$25.32
+30.6%
16.6%US$32.00US$17.00US$21.6917
May ’24US$18.83
US$25.02
+32.9%
16.9%US$32.00US$17.00US$21.9317
Apr ’24US$19.41
US$24.97
+28.6%
16.8%US$32.00US$17.00US$23.6818
Mar ’24US$17.47
US$25.25
+44.5%
17.1%US$32.00US$17.00US$22.2418
Feb ’24US$17.56
US$25.05
+42.7%
16.8%US$32.00US$17.00US$21.7517
Analyst Price Target
Consensus Narrative from 22 Analysts
US$35.93
Fair Value
6.3% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 22:48
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exelixis, Inc. is covered by 42 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research